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Under-treatment of elderly patients with
ovarian cancer: a population based study
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and Faïza Bessaoud1*
Abstract
Background: Ovarian cancer is the fourth most common cancer among women in France, and mainly affects the
elderly. The primary objective of this study was to compare treatment of ovarian cancer according to age.
Methods: All patients with invasive cancer (n = 1151) diagnosed between 1997 and 2011 in the Herault
Department of southern France were included. Demographic data (age, area of residence), cancer characteristics
(stage, histology, grade) and treatment modality (type, period and location of treatment) were analysed. Univariate
and multivariate logistic regression was used to compare treatment by age.
Results: Ovarian cancer was less treated in elderly compared to younger patients, regardless of the type of
treatment. This difference was more pronounced for chemotherapy, and was maximal for surgery followed by
chemotherapy (odds ratio (OR) for surgery for patients aged >70 vs those aged <70 years = 0.47 [0.24–0.91], OR for
chemotherapy, age >70 vs <70 = 0.30 [0.16–0.55] and OR for surgery plus chemotherapy, age >70 vs <70 = 0.14
[0.08–0.28]). This effect of age was independent of other variables, including stage and grade. The probability of
receiving standard treatment, in accordance with recommendations, was reduced by 50 % in elderly patients
compared to their younger counterparts. Overall and net survival of elderly patients with standard treatment was
similar to those of younger patients treated outside standard treatment.
Conclusions: Elderly women with ovarian cancer were therapeutically disadvantaged compared to younger
women. Further studies including co morbidities are necessary to refine these results and to improve therapeutic
management of elderly patients with ovarian cancer.
Keywords: Ovarian cancer, Elderly, Treatment pattern, Guidelines-recommended therapy, Survival
Background
Cancer is the second leading cause of death in women
after cardiovascular disease. In France, the number of
new cancer cases increased significantly between 1980
and 2012 [1]. This increase is largely due to the increase
in population and aging, which automatically increases
the number of cases, particularly those occurring in the
elderly. In Western countries, ovarian cancer remains
the leading gynecological cause of death [2]. Ovarian
cancer represents the 6th cause of cancer and the 4th
cause of death in women in France. Nearly 4600 new
cases are diagnosed, and nearly 3100 women die of this
disease annually in France [1].
Ovarian cancer is a disease that is most common in
the elderly, and its incidence increases with age to reach
a peak during the 7th decade of life [3]. The populations
in western countries tend to be aging; hence, the num-
ber of elderly women needing to be treated for ovarian
cancer can be expected to increase [4].
Prior studies have shown that elderly women, com-
pared to their younger counterparts, are more likely to
have a delayed diagnosis or an advanced stage at diagno-
sis [5–7]. Furthermore, in elderly patients, the tumor
characteristics (such as histology and stage) are often
not investigated [8]. Furthermore, treatment of this dis-
ease is complex, consisting in consensus-based treat-
ment defined according to stage and tumor grade.
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Surgery and/or chemotherapy constitute the cornerstone
of ovarian cancer treatment [9]. Such taxing treatment
requires good physiological capacity, and many older
people may have diminished physiological reserves, es-
pecially due to the presence of comorbidities. Conse-
quently, many authors have addressed the issue of
treatment of ovarian cancer in older women, highlight-
ing significant disparities in senior health care. Several
studies [4, 10–12] have shown that elderly patients with
ovarian cancer have a poorer prognosis compared to
their younger counterparts, due in part to under-
treatment. Furthermore, when the elderly are treated,
standard treatment guidelines are less frequently applied
than for younger patients, and the elderly receive less
aggressive therapy, even in the absence of comorbidity
[13–15].
Based on these findings, our study hypothesis was that
elderly women with ovarian cancer are under-treated.
The main objective of this work was to investigate
whether treatment practices differed between elderly
women with ovarian cancer and their younger
counterparts.
Methods
Study population
This observational study included all ovarian cancer
cases (ICD-O-3 code C56.9) (n = 1151) occurring among
women diagnosed between January 1997 and December
2011, residing in the Hérault department of southern
France. We excluded all patients with borderline tumors.
Data recorded
The tumor registry has existed in the Hérault depart-
ment since 1983 and covers a population of more than
one million inhabitants (1 062 036 according to the
2011 census). The registry records all cases of cancer oc-
curring in this department in a continuous and exhaust-
ive manner. All cases of ovarian cancer included in the
present study were validated through systematic verifica-
tion across original medical records. Demographic data,
tumor characteristics (date of incidence, stage and grade
at diagnosis) and treatment data (actual treatment given
and location of treatment), as well as survival were de-
termined in a reliable manner. This study was approved
by two Ethics Committees for studies using human sub-
jects (the Consultative Committee on Data Processing
for Medical Research and the National authority for the
protection of privacy and personal data) which provided
approval to access routinely collected population-based
cancer data in Hérault and which advocates that all
medical information is confidential and anonymous and
the need for individual informed consent was waived on
the basis that the registry collects data already available
in the patients’ medical files.
Variables
Outcome variable
The primary outcome variable analyzed in this study
was the type of treatment. Firstly, this variable was used
in binary form, i.e. patient had surgery (yes/no) and pa-
tient had chemotherapy (yes/no). Subsequently, it was
analyzed in the form of treatment sequences or patterns.
Four patterns were used (surgery alone, surgery followed
by chemotherapy, chemotherapy alone or neo adjuvant,
and no treatment). These patterns were derived from
treatment guidelines and recommendations correspond-
ing to the existing consensus for the treatment of ovar-
ian cancer. The treatment strategy depended on the
tumour stage and grade. Surgery was generally the first
line treatment, with a view to full tumour resection. Sur-
gery alone may be sufficient to treat early grade cancers
(stages IA/IB and grade 1). For intermediate stage can-
cers (stages IC, II, III and grades 1–3), surgery is
followed by chemotherapy with a view to eliminating
any residual cancer cells and reducing the risk of relapse.
When the tumour is diagnosed at an advanced stage
(stage IV), chemotherapy may be performed before sur-
gery to reduce the size of the tumour before resection,
or may be used as a stand-alone approach. Finally, in
our last model, we created a binary variable to record
whether standard treatment was applied (yes/no), ac-
cording to whether guidelines-recommended treatment
was applied or not.
Explanatory variables
The main explanatory variable in this study was the age
at diagnosis, divided into two classes, namely ≤70 years
and >70 years old. Other variables considered were
demographic data and cancer characteristics (stage,
grade, histology). We recorded the area of residence
(urban or rural). Tumour stage was recorded and classi-
fied into four groups according to the TNM classifica-
tion system and International Federation of Gynecology
and Obstetrics (FiGO) staging system (UICC 6th
edition). In our study, tumor histology was classified ac-
cording the World Health Organization (WHO) classifi-
cation and grouped into epithelial type; other; or
“unknown histology”, when there was no microscopic
confirmation or no histological testing.
The tumor grade was coded in three categories: well-
differentiated (grade 1), moderately differentiated (grade
2), and poorly differentiated (grade 3) or unknown. The
healthcare establishment where the first treatment took
place was categorized into: private for-profit clinics, pub-
lic university teaching center (Public Univ.), public non-
academic (Public non Univ.) and Unknown or Outside
the Hérault department (Unknown).
The study period was divided into three classes: before
(≤2002), during (2003–2007) and after (≥2008) the
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national cancer plan. The national cancer plan mobilizes
a national foundation for the organization healthcare
and prevention, and provides support for research in the
field of cancer. This plan includes the creation of an
oncogeriatrics task force responsible for the promotion
and coordination of projects in the field of epidemiology,
prevention and adaptation of treatments and clinical tri-
als in the elderly population [16]. The variables recorded
for survival analysis included the date of diagnosis, the
date of last contact and vital status (alive/deceased).
Vital status was obtained from National Institute of Sta-
tistics and Economic Studies (INSEE) and the National
Directory for the Identification of Individuals (RNIPP).
The descriptive and comparative part of this study
covers the period 1997–2011 and the survival analysis
covers the period 1997–2010, with follow-up ending on
30/06/2013. Our descriptive and comparative analysis
focuses on 1151 cases and the survival analysis on 1056
cases (692 deaths and 364 censored).
Statistical analysis
The chi square or Fisher’s exact test were used, as
appropriate, to compare cancer characteristics accord-
ing to age. Univariate and multivariate analysis using
logistic regression were used to identify the associ-
ation between treatment (Surgery and Chemotherapy:
yes/No) and age, adjusted for other factors such as
stage, grade, histological research, treatment location,
and area of residence. Multivariate logistic regression
was used to analyze the treatment pattern (surgery
alone, surgery followed by chemotherapy, chemother-
apy alone or neo-adjuvant chemotherapy, vs. no treat-
ment) according to age. The Kappa test was used to
assess agreement between the treatment administered
and the treatment recommended by current guide-
lines. Overall survival was estimated according the
Kaplan-Meier method. Net survival (survival if the
cause of death under consideration was the only
cause of death) is now recommended as a substitute
for relative survival methods in current use, to evalu-
ate population-based cancer survival [17, 18]. We es-
timated net survival using the non-parametric Pohar
Perme estimator [19], which is based on the mortality
rate of the general population and provides unbiased
estimates of net survival. Overall survival curves were
compared using the log rank test. All tests were two-
sided and a p-value <0.05 was considered statistically
significant. A Cox regression model was used to esti-
mate hazard ratios for overall mortality, with adjust-
ment for age and other confounding factors including
grade and stage. We verified the conditions of appli-
cation of the model by testing the proportionality of
risks. All statistical analyses were performed with the
R software package. Net survival analysis was
performed using the “relsurv” package specific to rela-
tive survival analysis.
Results
Among 1151 women diagnosed with invasive ovarian
cancer, 38.9 % were elderly (≥70 years old). The average
age was 64.7 years, median age was 66 years.
Table 1 shows the characteristics of ovarian cancer ac-
cording to age at diagnosis. Compared to younger women,
elderly patients more frequently had their cancer diag-
nosed at a more advanced stage (p <0.0001); 12 % of eld-
erly women presented stage I, compared to 24.5 % for
younger women. Histological testing was often not per-
formed or unknown in elderly women (p < 0.001) and the
cancer grade was also more often unknown (p < 0.001).
Younger women tended to be treated in Public university
Table 1 Characteristics of ovarian cancer patients according to
age
Age ≤70 years
(N = 703)
>70 years
(N = 448)
P value for Chi2
N % N %
Stage <0.0001
I 172 24.5 % 54 12.1 %
II 47 6.7 % 24 5.4 %
III 328 46.7 % 227 50.7 %
IV 122 17.4 % 115 25.7 %
Unkown 34 4.8 % 28 6.3 %
Grade 0.0003 (0.0676*)
1 62 8.8 % 19 4.3 %
2 120 17.1 % 61 13.6 %
3 150 21.3 % 79 17.6 %
Unkown 371 52.8 % 289 64.5 %
Histology <0.0001
Epithelial 655 93.2 % 379 84.6 %
Other 39 5.6 % 8 1.8 %
No histology 9 1.3 % 61 13.6 %
Treatment location 0.0137 (0.0676*)
Private 386 54.9 % 265 59.1 %
Public Univ. 240 34.1 % 120 26.8 %
Public non-Univ. 51 7.3 % 33 7.4 %
Unkown 26 3.7 % 30 6.7 %
Period of diagnosis 0.5509
≤2002 279 39.7 % 164 36.6 %
2003–2007 220 31.3 % 144 32.1 %
≥2008 204 29,0 % 140 31.3 %
Area of residence 0.5343
Urban 598 85.6 % 387 86.4 %
Rural 105 14.9 % 61 13.6 %
*p-value when modality ‘Unknown’ was excluded from analysis
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hospitals, whereas elderly patients tended to be treated in
private clinics, although the difference was not statistically
significant (p = 0.06). The period of diagnosis and the area
of residence did not differ according to age.
Tables 2 and 3 show the associations between treat-
ment (surgery or chemotherapy) and age, and other po-
tential confounding factors. Compared to their younger
counterparts, elderly women less often underwent surgi-
cal treatment (60.9 % versus 89.6 %, p < 0.001) and
chemotherapy (57.4 % versus 76.4 %, p < 0.001). After
adjustment for cancer characteristics (stage, grade,
histology and other adjuvant treatments), we observed
that elderly women were 3.6 less likely to have surgical
treatment (OR = 0.28 [0.19–0.41]) and three times less
likely to undergo chemotherapy (OR = 0.34 [0.24–0.48]).
Based on the assumption that the association be-
tween treatment and age could differ according the
stage at diagnosis, we performed a stratified analysis,
which showed that the association between age and
surgery was significantly different according to cancer
stage. For early stages I-II, surgical treatment did not
differ according age (OR >70 vs ≤70 = 0.17 [0.01–
Table 2 Univariate and multivariate analysis of the association between demographic and cancer characteristics and treatment by
surgery
Surgery (N = 903) No surgery (N = 243) p Univariate analysis Multivariate analysis
N % N % OR (95%CI) ORa (95%CI)
Age ≤70 630 89.6 % 73 10.4 % <0.0001 1 1
>70 273 60.9 % 175 39.1 % 0.18 (0.13–0.25) 0.28 (0.19–0.41)
Stage
I-II 295 99.3 % 2 0.7 % <0.0001 125.59 (30.5–516.35) 153.42 (35.67–659.9)
III 448 80.7 % 107 19.3 % 3.56 (2.56–4.97) 4.46 (2.97–6.72)
IV 128 54.0 % 109 46.0 % 1 1
Unkown 32 51.6 % 30 48.4 % 0.91 (0.52–1.6) 3.69 (1.33–10.25)
Adjuvant treatment yes 677 84.3 % 126 15.7 % <0.0001 2.94 (2.17–3.85) 2.51 (1.58–3.97)
no 226 64.9 % 122 31.5 % 1 1
Histology <0.0001
Epithelial 856 82.8 % 178 17.2 % 1 1
Other 46 97.9 % 1 2.1 % 9.56 (1.31–69.81) 8.4 (1.05–67.44)
No histology 1 1.4 % 69 98.6 % 0.003 (0.001–0.02) 0.01 (0.14–0.79)
Grade <0.0001
1 73 90.1 % 8 9.9 % (0.4595*) 1 1
2 763 97.7 % 18 2.3 % 0.99 (0.41–2.39) 1.94 (0.72–5.28)
3 198 86.5 % 31 13.5 % 0.70 (0.31–1.59) 1.63 (0.63–4.19)
Unkown 469 71.1 % 191 28.9 % 0.27 (0.13–0.57) 0.82 (0.35–1.96)
Treatment location
Private 543 83,4 % 108 16.6 % 0.0001 1.37 (0.99–1.89) 2.00 (1.30–3.08)
Public Univ. 283 78,6 % 77 21.4 % (0.0015*) 1 1
Public non-Univ. 57 67,9 % 27 32.1 % 0.57 (0.34–0.97) 0.65 (0.31–1.34)
Unkown 20 35,7 % 36 64.3 % 0.15 (0.08–0.28) 0.33 (0.14–0.79)
Period of diagnosis
≤2002 348 78.6 % 95 21.4 % 0.4751
2003–2007 292 80.2 % 72 19.8 %
≥2008 263 76.5 % 81 23.5 %
Area of residence
Rural 132 79.5 % 34 20.5 % 0.7184
Urban 771 78.3 % 214 21.7 %
OR (95%CI) Odd Ratio and 95 % Confidence Interval, ORa Odd Ratios were adjusted for factors associated with treatment with a p-value <0.10 by univariate
analysis
*p-value when modality ‘Unknown’ was excluded from analysis
Fourcadier et al. BMC Cancer  (2015) 15:937 Page 4 of 10
4.45], p = 0.2858). However, for stage III, there was a
significant association between surgery and age, with
elderly patients having a significantly lower likelihood
of surgery (OR >70 vs ≤70 = 0.17 [0.09–0.30]), and
there was a similar, albeit non-significant trend for
stage IV (OR >70 vs ≤70 = 0.56 [0.31–1.03]). The as-
sociation between chemotherapy and age was also
stratified according stage at diagnosis, but there were
no significant differences. The regression models in-
cluding an interactive term between age and stage
confirmed the findings of our stratified analysis.
With the exception of the area of residence, all vari-
ables were significantly related to the three different
treatment pathways (surgery alone, surgery + chemother-
apy, chemotherapy alone or neo-adjuvant) (Table 4).
Multivariate regression adjusted for cancer characteris-
tics (stage, grade, histology), treatment location and
period of diagnosis showed that there was a significant
difference between elderly patients and their younger
counterparts in terms of all treatment sequences. Re-
gardless of the treatment pattern, elderly patients re-
ceived less treatment. We observed a gradient effect
Table 3 Univariate and multivariate analysis of the association between demographic and cancer characteristics and treatment by
chemotherapy
Chemotherapy (N = 794) No chemotherapy (N = 357) p Univariate Multivariate
N % N % OR (95 % CI) ORa (95 % CI)
Age ≤70 537 76.4 % 166 23.6 % <0.0001 1 1
>70 257 57.4 % 191 42.6 % 0.42 (0.32–0.54) 0.34 (0.24–0.48)
Stage
I-II 147 49.5 % 150 50.5 % <0.0001 0.36 (0.25–0.52) 0.13 (0.08–0.21)
III 459 82.7 % 96 17.3 % 1.77 (1.23–2.54) 1.28 (0.83–1.97)
IV 173 73.0 % 64 27.0 % 1 1
15 24.2 % 47 75.8 % 0.12 (0.06–0.23) 0.14 (0.06–0.32)
Adjuvant treatment yes 677 74.2 % 235 25.8 % 3.03 (2.22–4) 2.60 (1.67–4.05)
no 117 49.0 % 122 51.0 % <0.0001 1 1
Histology <0.0001
Epithelial 765 74.0 % 269 26.0 % 1 1
Other 17 36.2 % 30 63.8 % 0.20 (0.11–0.37) 0.37 (0.18–0.76)
No histology 12 17.1 % 58 82.9 % 0.07 (0.04–0.14) 0.23 (0.11–0.48)
Grade <0.0001
1 48 59.3 % 33 40.7 % 1 1
2 144 79.6 % 37 20.4 % 2.68 (1.51–4.74) 2.01 (1.04–3.89)
3 197 86.0 % 32 14.0 % 4.23 (2.37–7.56) 2.85 (1.48–5.50)
Unkown 405 61.4 % 255 38.6 % 1.09 (0.68–1.75) 1.31 (0.75–2.27)
Treatment location
Private 467 71.7 % 184 28.3 % <0.0001 0.91 (0.68–1.22) 1.15 (0.81–1.63)
Public Univ. 265 73.6 % 95 26.4 % 1 1
Public non-Univ. 40 47.6 % 44 52.4 % 0.33 (0.20–0.53) 0.41 (0.23–0.75)
Unkown 22 39.3 % 34 60.7 % 0.23 (0.13–0.42) 0.37 (0.17–0.78)
Period of diagnosis
≤2002 298 67.3 % 145 32.7 % 0.1637 1 1
2003–2007 265 73.0 % 98 27.0 % 1.30 (0.96–1.77) 1.78 (1.23–2.57)
≥2008 231 67.2 % 113 32.8 % 0.99 (0.74–1.34) 1.26 (0.87–1.83)
Area of residence
Rural 115 69.3 % 51 30.7 % 0.9297
Urban 679 68.9 % 306 31.1 %
OR (95%CI) Odd Ratio and 95 % Confidence Interval, ORa Odd Ratios were adjusted for factors associated with treatment with a p-value <0.10 by
univariate analysis
*p-value when modality ‘Unknown’ was excluded from analysis
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between treatment and age linked to the introduction of
chemotherapy and its association with surgery: for sur-
gery OR >70 vs ≤70 years = 0.46 [0.16–0.55], for chemo-
therapy OR >70 vs ≤70 years = 0.29 [0.16–0.55] and OR
>70 vs ≤70 years = 0.13 [0.08–0.25] for surgery plus
chemotherapy (data not shown).
The concordance test (data not shown) showed that
younger patients had a 34 % [26–42 %] chance of receiv-
ing guidelines-recommended therapy, whereas elderly
patients had only a 19 % [11–27 %] chance, p <0.001. By
univariate analysis, the variables associated with the ap-
plication of standard (guidelines-recommended) treat-
ment were age (p <0.0001), stage (p = 0.0019) and
histology (p = 0.0443). Multivariate analysis showed that
elderly patients had more than 50 % less likelihood of re-
ceiving guidelines-recommended therapy (OR = 0.48
[0.36–0.64]) (Table 5).
For the survival analysis, 1056 women were
followed between 1997 and 2010, including 692
deaths and 364 censored. The median was
39.4 months for overall survival, and 39.9 for net sur-
vival. Overall and net survival plotted by the Kaplan
Meier stratified according to the implementation (or
not) of standard guidelines-recommended therapy,
showed that elderly patients had poorer survival than
younger patients (log-rank test p < 0.001), all the more
so when guidelines-recommended was not adminis-
tered in the elderly (Fig. 1a and b). Use of guidelines-
recommended therapy improved survival in elderly
women, bringing it up to a level almost equivalent to
survival in younger women who did not receive
guidelines-recommended treatment. There was no sig-
nificant difference in use of guidelines-recommended
therapy in older vs younger women for survival dura-
tions <10 years (p = 0.20). However, a significant dif-
ference was observed when overall survival exceeded
10 years (p = 0.02) and a trend towards a difference
was observed for net survival (p = 0.08). In a Cox re-
gression model for overall mortality, including terms
for age, stage, grade, histology and standard of treat-
ment (Table 6), older age (>70 years) was associated
with an almost twofold increase in the risk of death,
and stage III and stage IV disease were associated
with significantly greater risks of death compared
with stage I disease (hazard ratios of 3.8 and 5.2, re-
spectively). Application of standard (guidelines-recom-
mended) therapy was also associated with a
significant reduction in the relative risk of death
Table 4 Demographic and cancer characteristics by treatment patterns
No treatment Surgery alone Surgery + Chemotherapy Chemotherapy alone or neo adjuvant P-value
Mod. N % N % N % N %
Age <= 70 years 28 3.9 % 138 19.7 402 57.3 134 19 <0.0001
>70 years 96 21.5 % 93 20.9 % 142 31.9 115 25.8
Stage 1-II 1 0.3 % 149 50.2 % 139 46.8 % 8 2.7 % <0.0001
III 50 9.0 % 45 8.1 % 325 58.7 % 134 24.2 %
IV 46 19.6 % 17 7.2 % 70 29.8 % 102 43.4 %
Unkown 27 43.6 % 20 32.3 % 10 16.1 % 5 8.1 %
Grade 1 2 2.5 % 31 38.3 % 34 41.9 % 14 17.3 % <0.0001
2 4 2.2 % 32 17.8 % 108 60 % 36 20 %
3 9 3.9 % 22 9.7 % 133 58.3 % 64 28.1 %
Unkown 109 16.5 % 146 22.2 % 269 40.8 % 135 20.5 %
Histology No histology 58 82.9 % 0 0 % 1 1.4 % 11 15.7 % <0.0001
Other 0 0 % 30 63.8 % 16 34.0 % 1 2.1 %
Epithelial 66 6.4 % 201 19.5 % 527 52.1 % 237 22.9 %
Period of diagnosis <=2002 46 10.4 % 99 22.4 % 219 49.6 % 78 17.7 % 0.0003
2003–2007 34 9.4 % 64 17.7 % 193 53.2 % 72 19.8 %
> = 2008 44 12.9 % 68 19.8 % 132 34.5 % 99 28.9 %
Treat. Private 41 6 % 141 21.7 % 336 51.8 % 131 20.2 % 0.0001
location Public Univ 33 9.2 % 62 17. 163 45.4 % 101 28.1 %
Public non-Univ 20 23.8 % 24 28.6 % 30 35.7 % 30 11.9 %
Unknown 30 53.6 % 4 7.1 % 15 26.8 % 7 12.5 %
Area of residence Rural 17 10.3 % 34 20.6 % 82 49.7 % 32 19.4 % 0.8609
Urban 1077 10.9 % 197 20.0 % 462 47 % 217 22.1 %
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(hazard ratio = 0.74) after adjustment for age, stage,
grade and histology.
Discussion
Our study shows that elderly women with ovarian cancer
receive less treatment than their younger counterparts, re-
gardless of the type of treatment considered. We found
that the difference between age groups was greater for
chemotherapy than for surgery, and was highest for the
combination of surgery plus chemotherapy. The cancer
characteristics being equal, elderly women had less chance
of receiving standard therapy, i.e. the recommended treat-
ment by current guidelines. Elderly patients in whom
guidelines-recommended treatment was not applied had
poorer likelihood of survival as compared to elderly pa-
tients who received guidelines-recommended therapy, and
as compared to younger women. In line with previous re-
ports [4–6, 13, 20, 21], our findings also show that ovarian
cancer in elderly women were more often discovered at an
advanced stage as compared to younger women, and are
less often submitted to histological testing.
We found that elderly women with ovarian cancer were
three times less likely to have chemotherapy than younger
women. As regards surgery, elderly patients were 3.6 times
less likely to have surgical treatment than their younger
counterparts. The association between surgical treatment
and age was different according to cancer stage at diagno-
sis, since treatment differences were age-related for the
higher stages rather than lower stages. Our results are in
line with several previous studies [4, 5, 11, 13, 14, 22], and
in particular, our findings are concordant with two recent
studies [11, 13] showing that age is an independent pre-
dictor of non-administration of either surgery or
chemotherapy.
Despite medical progress, and the introduction of a na-
tional cancer plan by the French government in 2003 to
promote better management of cancer patients and high-
light the problem of health inequity, our study, like several
others [5, 11, 13, 14, 20], found that elderly patients were
less likely to be treated as aggressively as younger patients.
The association between treatment and age showed a gra-
dient effect linked to the use of chemotherapy. Indeed,
compared to younger patients, elderly women had less
surgery, and the chances of being treated decreased even
more when chemotherapy was the treatment of choice,
and even further still when chemotherapy was combined
with surgery. Furthermore, we showed than standard
guidelines-recommended therapy was less frequently ap-
plied in the elderly, and hence, elderly patients were 50 %
less like to receive standard therapy than younger patients.
The reasons for this discrepancy could be related to more
advanced disease, or to functional impairment in the eld-
erly, which may be incompatible with implementation of
recommended treatment. However, some studies have re-
ported that age remains an independent predictor of
under-treatment. Recent reports [4, 11, 14, 23] have
Table 5 Multivariate analysis of the factors associated with application of guidelines-recommended therapy
Standard treatment applied = No Standard treatment applied = yes ORa (95 % CI)
N % N %
Age <= 70 169 30.2 % 390 69.8 % 1
>70 153 47.9 % 166 52,0 % 0.48 (0.36–0.64)
Stage I-II 60 31.4 % 131 68.6 % 1
III 172 34.6 % 325 65.4 % 1.81 (1.2–2.81)
IV 90 47.4 % 100 52.6 % 1.64 (1.16–2.33)
Grade 1 24 32.8 % 49 67.1 % 1
2 56 32.9 % 114 67.1 % 1.17 (0.64–2.14)
3 73 34.1 % 141 65.9 % 1.17 (0.64–2.11)
Unknown 169 40.1 % 252 59.9 % 0.95 (0.55–1.67)
Histology No histology 6 60,0 % 4 40,0 % 1
Epithelial 305 35.9 % 544 64.1 % 0.62 (0.17–2.3)
Other 11 57.9 % 8 42.1 % 0.37 (0.14–0.98)
Treatment location Private 188 35.9 % 335 64.1 % 1.33 (0.97–1.82)
Public Univ. 122 39.7 % 170 60.3 % 1
Public non-Univ. 16 32,0 % 34 68,0 % 1.56 (0.78–3.06)
Unknown 6 26.1 % 17 73.9 % 0.96 (0.54–1.67)
OR (95%CI) Odd Ratio and 95 % Confidence Interval, ORa Odd Ratios were adjusted for factors associated with treatment with a p-value <0.10 by
univariate analysis
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suggested that elderly patients are much less likely to re-
ceive standard treatment, even after adjusting for comor-
bidities. Maas et al reported in a population of patients
with FIGO II or III ovarian cancer that elderly (≥70 years)
patients were seven times less likely to receive guidelines-
recommended treatment (surgery + chemotherapy) than
younger patients, even after adjustment for comorbidities
(OR ≥70 vs <70 years = 0.14 [0.07 to 0, 21] and OR comor-
bidities vs no comorbidities = 0.91 [0.78 to 0.93]) [14].
This suggests that under treatment cannot be explained
by poorer functional status in elderly patients. Other po-
tential explanatory factors could include patient and/or
physician choices.
The strengths of this study include its 14 year coverage
of all cancer cases in the Herault Department, the rela-
tively large size (1151 incident cases) and its population-
based nature. We analyzed the variable “treatment” in
the form of treatment sequences, which is rarely found
in the literature, and confirmed our hypothesis that eld-
erly women with ovarian cancer are under-treated.
Another strongpoint is the use of a variable to take com-
pliance with guidelines into account, by evaluating the
application of guidelines-recommended therapy. This
variable allowed us to highlight that older women were
two times less likely to receive guidelines-recommended
treatment than younger women, and this had a
Fig. 1 10-year overall survival (panel a) and net survival (panel b) by age and treatment recommendation
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deleterious effect on overall survival. Indeed, overall sur-
vival in elderly women who did not receive standard
treatment was worse than overall survival younger
women, but it was also worse than elderly women who
did receive standard treatment.
Our study suffers from some limitations. The analysis
did not take into account factors such as comorbidities
or functional status because these variables were not
available in the registry. However, the fact that overall
survival in this study was similar to the net survival (de-
fined as the survival that would be observed if cancer
was the only possible cause of death) suggests that the
effect of comorbidities could be negligible, and probably
did not modify the independent effect of age on
treatment.
In our study, we chose to present the results in terms
of net survival, as calculated using the Pohar Perme esti-
mator [19]. This estimator of net survival has been
shown in the literature to be more appropriate for regis-
try data [17, 18]. This is due to the fact that classical
“relative-survival” methods used to estimate net survival
provide biased estimates. The Pohar-Perme net survival
estimator may be prone to random variation and result
in biased estimates when exact follow-up times are not
available, or when follow-up is incomplete [24]. How-
ever, this situation is avoided in our study, since survival
data (i.e. follow-up times) recorded in the registry was
exhaustive, we have exact data on the number of deaths
or patients lost to follow-up, with the exact dates when
the events occurred. Our analysis is therefore not at risk
of biased estimates, since the exact follow-up times are
known, and the follow-up is fully complete.
Second, there was a considerable proportion of missing
data. However, our data show that diagnostic tests (grade,
stage, histology) are more often overlooked in elderly pa-
tients vs their younger counterparts. The fact that there
are many patients with unknown histology or unknown
grade is precisely the reflection of this phenomenon, as
this indicates that the diagnosis is not pursued in detail to
obtain this information in elderly patients. This could also
be explained by the fact that the group of patients who
underwent surgery comprises patients who had surgery
after having chemotherapy, which may render analysis of
the surgical specimens more difficult, or even impossible,
thus leading to more missing data.
Furthermore, no information about the reasons for
non-treatment, or the treatment modalities (e.g. type of
surgery: complete or incomplete debulking) was avail-
able in our data. As highlighted by literature data [25],
there exist large inequalities in access to healthcare and
this is particularly valid for the elderly. We cannot ex-
clude the fact that elderly patients differ with respect to
their tolerance of treatment and their comorbidities, and
some elderly patients might yield benefit from more ag-
gressive therapy than they actually receive in reality. Pre-
vious studies [21, 26, 27] have indicated that in general,
the elderly tolerate surgery well and are able to tolerate
chemotherapy in the same conditions and modalities
(schedule, dosage, complete courses…) as their younger
counterparts. Therefore, age itself does not constitute
the sole reason for withholding treatment. Although age
was found to have an independent effect on under-
treatment in our study, further research is warranted to
evaluate whether this effect persists when individual co-
morbidities and treatment patterns (e.g. type of surgery,
duration of treatment, completion of treatment,…) are
accounted for, as these are all factors that may contrib-
ute to under-treatment of elderly patients.
Other variables that were not available in our study
may also influence the association between treatment
and age. One study reported that being cared for by a
gynecologic oncologist influenced the type of treatment
administered, and for advanced stages (FIGO III or IV),
treatment by a gynecologic oncologist increased the
probability of receiving chemotherapy twofold [10].
Other variables such as marital status or socio-economic
status also deserve be taken into account, since some
studies have suggested that single people or people with
a low level of education are more likely to have chemo-
therapy [15].
Conclusion
In conclusion, our study showed that elderly were under
treated. For similar cancer characteristics, the probability of
undergoing guidelines-recommended treatment was two-
times lower in elderly patients compared to the younger
Table 6 Adjusted effect of age on overall mortality by
multivariate Cox regression analysis
HR 95 % CI
Age <= 70 1
>70 1.96 (1.65–2.33)
Stage I–II 1
III 3.78 (2.84–5.03)
IV 5.18 (3.77–7.12)
Grade 1 1
2 1.36 (0.90–2.05)
3 1.05 (0.69–1.58)
Unknown 1.38 (0.84–2.02)
Histology No histology 1.52 (0.80–2.88)
Epithelial 1
Other 1.35 (0.69–2.64)
Standard treatment No 1 (0.62–0.89)
Yes 0.74
HR (95%CI) Hazard Ratio and 95 % Confidence Interval
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counterparts. Elderly patients have improved likelihood of
survival when recommended treatment is applied. Further
research, however, is warranted to investigate whether the
independent effect of age persists in the presence of co-
morbidity. Acknowledging the under-treatment of elderly
patients constitutes a first step in the broader process of
improving therapeutic management of these patients. Sev-
eral possibilities for improving patterns of care have been
proposed. Geriatric assessment could help determine which
patients are too frail to undergo standard treatment, and is
essential for the initiation of treatment, particularly burden-
some therapy.
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